10th week of 2022 patent applcation highlights part 25 |
Patent application number | Title | Published |
20220073482 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON - A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities. | 2022-03-10 |
20220073483 | METHOD OF MAKING A BIPHENOL DIANHYDRIDE COMPOSITION, METHOD FOR PURIFICATION OF A BIPHENOL DIANHYDRIDE, AND POLY(ETHERIMIDE)S DERIVED FROM THE BIPHENOL DIANHYDRIDE - A method of making a biphenol dianhydride composition includes heating a first solution including a biphenol tetraacid of the formula (I) wherein Ra, Rb, p and q are as defined herein; at least one of sodium ions, potassium ions, calcium ions, zinc ions, aluminum ions, iron ions, phosphate ions, sulfate ions, chloride ions, nitrate ions, and nitrite ions; and a non-halogenated solvent. The first solution is heated under conditions effective to provide a second solution including the corresponding biphenol dianhydride, the at least one of sodium ions, potassium ions, calcium ions, zinc ions, aluminum ions, iron ions, phosphate ions, sulfate ions, chloride ions, nitrate ions, and nitrite ions, and the non-halogenated solvent. | 2022-03-10 |
20220073484 | SELECTIVE EXTRACTION METHOD FOR NATURAL SUBSTANCES - An extraction method for nonpolar natural substances includes: a step of conducting extraction of natural raw materials to prepare a first liquid extract; a step of mixing the first liquid extract with a phase separation composition containing a lipophilic solubilizer and water, and conducting a second extraction; and a step of isolating the supernatant of the phase-separated solution to obtain non-polar natural substances. | 2022-03-10 |
20220073485 | Functionalised Amine Derivatives as IL-17 Modulators - A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders. | 2022-03-10 |
20220073486 | METHOD FOR SYNTHESIZING MYRICETIN - This application discloses a method for synthesizing myricetin, which includes the following steps: adding an alkaline solution to an aqueous solution of dihydromyricetin, and heating under a reflux state after the addition; adding an aqueous solution of selenium dioxide, stirring at a reflux temperature after the addition, and cooling to room temperature after the reaction is complete; adding acid to adjust pH, stirring, rotary evaporation, stirring, and filtering; adding an aqueous solution of ethanol to a filter cake to make a slurry, filtering, washing the filter cake with the aqueous solution of ethanol, collecting the filter cake and drying to obtain red selenium; combining organic phases, spin-drying until there is no ethanol smell, precipitating a large amount of solids, filtering, and washing the filter cake with the aqueous solution of ethanol to obtain a yellow solid which is myricetin. The advantages of the disclosure are: 1. simple and easy to operate the reaction; 2. mainly using water and a small amount of ethanol as solvents so that the three wastes are less discharged; 3. recovering red selenium which is economically valuable; 4. obtaining myricetin of high purity; 5. serving multiple purposes with good economic benefits, and suitable for scale-up production. | 2022-03-10 |
20220073487 | BIOFLAVONOID IMPREGNATED MATERIALS - Cellulosic fibrous materials are described which are impregnated with a bioflavonoid composition, the bioflavonoid content of the composition comprising at least naringin and neohesperidin. The use of such impregnated materials is also described, for example as paper or bamboo towels and cardboard, as well as the process for impregnating the materials. | 2022-03-10 |
20220073488 | COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND - The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein. | 2022-03-10 |
20220073489 | MASS PRODUCTION AND APPLICATION OF DELTA 8 THC - A process of converting cannabidiol (CBD) to Δ | 2022-03-10 |
20220073490 | PROCESS FOR PREPARING DIOXOLANE - The present invention relates to a process for preparing dioxolane by reacting ethylene glycol with an aqueous solution of formaldehyde in the presence of an acid catalyst. The raw product comprising water, dioxolane and methanol is fed to a phase separation unit ( | 2022-03-10 |
20220073491 | DIOXIN DERIVATIVES, PREPARATION METHODS THEREOF, ELECTRON TRANSPORT LAYERS, OLED DEVICES AND DISPLAY PANELS - The present application provides a dioxin derivative, a preparation method thereof, an electron transport layer, an OLED device and a display panel. The dioxin derivative has a formula of | 2022-03-10 |
20220073492 | Method for the preparation of thiocarbonates - Provided is a process for the preparation of a compound with at least one five-membered cyclic monothiocarbonate group. A compound C1 with at least one halohydrin group is used as starting material. Compound C1 is reacted with phosgene or an alkyl chloroformate to give an adduct C2. The adduct C2 is reacted with a compound that includes anionic sulfur to obtain the compound with at least one five-membered cyclic monothiocarbonate group. | 2022-03-10 |
20220073493 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR - The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, which comprises the use of a compound of formula (I) or (I′), or a salt or solvate thereof. | 2022-03-10 |
20220073494 | 15-PGDH INHIBITORS - A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof. | 2022-03-10 |
20220073495 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA - The present disclosure provides, in part, compositions, kits and methods for treating or preventing an influenza viral infection by administering a therapeutically effective amount of an inhibitor of influenza viral M mRNA nuclear export to a subject in need. | 2022-03-10 |
20220073496 | NOVEL QUINOLINE DERIVATIVE INHIBITOR - Provided by the present invention is a novel quinoline derivative inhibitor, which has a structure represented by the following general formula (I). The compound of the present invention may selectively inhibit the TAM family of tyrosine kinases/and CSF1R kinase, and may be used for the treatment and/or prevention of diseases mediated by the abnormal expression of TAM family kinases/and CSF1R kinase receptors and/or ligands thereof. Furthermore, the compound of the present invention may be used to treat and/or prevent related diseases caused by NTRK, more specifically, said compound may be used for the treatment and/or prevention of drug-resistant related diseases caused by NTRK mutations. The definitions of each group are as shown in the description. | 2022-03-10 |
20220073497 | CRYSTAL OF PYRROLIDINE COMPOUND - The present invention provides a crystal of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid. | 2022-03-10 |
20220073498 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER - Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of autoimmune disorders or cancer. | 2022-03-10 |
20220073499 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: | 2022-03-10 |
20220073500 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF - Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. | 2022-03-10 |
20220073501 | COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH - The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer. | 2022-03-10 |
20220073502 | NOVEL TETRAZOLE AZASYDNONE - The present disclosure relates to a novel tetrazole azasydnone, a method of making the novel tetrazole azasydnone, and a method of using the novel tetrazole azasydnone as a primary explosive. In one aspect, the novel tetrazole azasydnone has a structure of formula I: | 2022-03-10 |
20220073503 | NITRIC OXIDE DONOR AND ANTI-OXIDANT COMPOUNDS - In some aspects, the present disclosure provides compounds of the formulae: (A), (B), (III), and/or (IV), wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, the compounds or compositions of the present disclosure may be used for the treatment of diseases or disorders, such as eye diseases and peripheral arterial diseases such as hind limb ischemia. | 2022-03-10 |
20220073504 | KIF18A INHIBITORS - Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A. | 2022-03-10 |
20220073505 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT - The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell limes, and thus can be usefully used in the treatment of lung cancer. | 2022-03-10 |
20220073506 | ALIPHATIC ACID AMIDE DERIVATIVE - The present invention relates to a compound represented by formula (1): | 2022-03-10 |
20220073507 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES - Compounds represented by the structural formula (1) where R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases. | 2022-03-10 |
20220073508 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. | 2022-03-10 |
20220073509 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS - The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer. | 2022-03-10 |
20220073510 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER - This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents. | 2022-03-10 |
20220073511 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN - Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions. | 2022-03-10 |
20220073512 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF - Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), and vascular diseases (e.g., atherosclerosis) in a subject. Provided are methods of inhibiting a INK (e.g., JNK1, JNK2, or JNK3) in a subject. | 2022-03-10 |
20220073513 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES - The present invention relates to compounds of Formula (II) and more preferably to 1H-pyrrolo[2,3-b]pyridine derivatives of formula (III) and related compounds. The variables are defined in the claims. The compounds are BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis of exemplary compounds as well as pharmacological data thereof (pages 61 to 72; examples 1 to 4; tables). An exemplary compound is e.g. 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-yl methyl)amino]benzenesulfonyl]benzamide (example 1). | 2022-03-10 |
20220073514 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT - Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided. | 2022-03-10 |
20220073515 | FORMS OF METHYL {4,6-DIAMINO-2-[1 (2-FLUOROBENZYL)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE - This present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I. Modification II. mono-DMSO solvate. sesqui-DMSO solvate and ¼-ethyl acetate solvate. | 2022-03-10 |
20220073516 | CRYSTALLINE SPIROCYCLIC COMPOUND, A DOSAGE FORM CONTAINING, A METHOD FOR USING IN TREATMENT OF DISEASE, AND A METHOD FOR RECRYSTALLIZING - There is a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate that exhibits an XRPD pattern having a characteristic peak at 19.05±0.20 (° 2θ). There is also a pharmaceutical composition containing the compound. There is also a dosage form containing the crystalline compound and one or more pharmaceutically acceptable excipients. There is also a method for crystallizing/recrystallizing the compound. There is also a method for treating or preventing a disease with the compound. | 2022-03-10 |
20220073517 | BLUE THERMALLY ACTIVATED DELAYED FLUORESCENT EMITTERS AND HOSTS BASED ON FUNCTIONALIZED IMIDAZOLYL GROUPS - Compounds of General Formula I may act as thermally activated delayed fluorescent emitters in organic electroluminescent devices. Compounds of General Formula I have donor and acceptor groups part of the same conjugated system. Devices incorporating compounds of General Formula I may have higher EQE and longer material lifetimes. | 2022-03-10 |
20220073518 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY - The present invention provides the compound represented by the following formula (I): | 2022-03-10 |
20220073519 | Compounds For Repressing Cancer Cell Growth - The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth. | 2022-03-10 |
20220073520 | CINNOLINE COMPOUNDS AND USES THEREOF - Cinnoline compounds of formula (I): | 2022-03-10 |
20220073521 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF - The present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative, a preparation method therefor, and the medical uses thereof. Particularly, the present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, and the uses thereof as a SHP2 inhibitor for use in the prevention and/or treatment of tumor or cancer, wherein each substituent in the general formula (I) is as defined in the description. | 2022-03-10 |
20220073522 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors - The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 2022-03-10 |
20220073523 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES - The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts. | 2022-03-10 |
20220073524 | JAK INHIBITOR COMPOUND AND USE THEREOF - The present disclosure relates to a class of JAK inhibitor compounds and uses thereof. Specifically, the present disclosure discloses a compound represented by formula (G), isotopically labeled compound thereof, or optical isomer thereof, geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. The present disclosure also relates to the application of the compounds in medicine. | 2022-03-10 |
20220073525 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 - This disclosure relates to modulating ubiquitin specific protease 1 (USP1) and provides novel chemical compounds useful as inhibitors of USP1, as well as various uses of these compounds. USP1 inhibiting compounds are useful in the treatment of diseases and disorders associated with USP1, such as cancer. | 2022-03-10 |
20220073526 | IL-17A INHIBITORS - The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis. | 2022-03-10 |
20220073527 | TYK2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. | 2022-03-10 |
20220073528 | TYK2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. | 2022-03-10 |
20220073529 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF - The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal. | 2022-03-10 |
20220073530 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process. | 2022-03-10 |
20220073531 | COMPOUNDS FOR ELECTRONIC DEVICES - The present invention relates to condensed N-heteroaromatic compounds, to processes for preparing these compounds, and to electronic devices containing said compounds. | 2022-03-10 |
20220073532 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS - This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof. | 2022-03-10 |
20220073533 | Method for Preparing Indolenaphthopyrans - Provided is a synthetic intermediate for the preparation of photochromic indolenaphthopyran compounds having the core skeletal structure of Formula (I): wherein m is 0 to 4, n is 0 to 4, R | 2022-03-10 |
20220073534 | Method for Controlled Release Using Mechanical Force - A general and modular mechanophore platform that efficiently releases a cargo molecule via a mechanically triggered cascade reaction is described, along with methods of synthesis and use thereof. The mechanophore platform comprises a stable Diels-Alder adduct mechanophore comprising a 2-furylcarbinol derivative as its diene component, wherein the 2-furylcarbinol derivative is, in turn, pre-loaded with a covalently attached cargo molecule, and wherein the Diels-Alder adduct mechanophore is embedded into a polymer chain or polymer network, such that the mechanophore platform undergoes the retro [4+2] cycloaddition reaction under mechanical force to reveal the unstable2-furylcarbinol derivative, which, in turn, easily decomposes under mild conditions to release its molecule cargo. | 2022-03-10 |
20220073535 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF - A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R | 2022-03-10 |
20220073536 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS - The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosus and/or its associated symptoms and multiple sclerosis and/or its associated symptoms. | 2022-03-10 |
20220073537 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 - The present invention relates to compounds of formula I: | 2022-03-10 |
20220073538 | Immunoproteasome Inhibitors - Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 2022-03-10 |
20220073539 | ORGANOMETALLIC CHAIN TRANSFER AGENTS - Embodiments relate to organometallic compositions that are useful for chain transfer during olefin polymerization. Such compositions are chain transfer agents comprising an organoaluminum compound of the formula Al(CH | 2022-03-10 |
20220073540 | CURABLE COMPOSITIONS COMPRISING UNSATURATED POLYOLEFINS - The present disclosure relates to unsaturated polyolefins and processes for preparing the same. The present disclosure further relates to curable formulations comprising the unsaturated polyolefins that show improved crosslinking. | 2022-03-10 |
20220073541 | SILICON ION COMPLEX ORGANIZED WITH CARBOXYLIC ACID, METHOD FOR MANUFACTURING COMPLEX, AND PRODUCT USING SAME - Proposed is a technology related to the ionization of silicon, and more particularly, to a technology for ionization by organizing silicon using a water-soluble silicate with a tricarboxylic acid or a dicarboxylic acid. This technology enables preparation and use of products containing an organized silicon ion complex in a variety of applications including foods such as water and beverages and medical products, as well as electrochemical applications. In particular, it is expected to treat and prevent various diseases caused by silicon deficiency by providing an organized form of silicon that does not exist as an ion in nature. | 2022-03-10 |
20220073542 | COMPOSITION FOR PHOTOELECTRIC DEVICE, AND IMAGE SENSOR AND ELECTRONIC DEVICE INCLUDING THE SAME - A composition for a photoelectric device includes a p-type semiconductor compound represented by Chemical Formula 1 and an n-type semiconductor compound, and an image sensor and an electronic device including the same: | 2022-03-10 |
20220073543 | SILACROWN ETHERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THERAPEUTIC APPLICATIONS THEREOF - Large ring silacrown ethers having at least fourteen ring atoms with at least one lipophilic or hydrophobic substituent on the ring and/or on the silicon atom are provided. Pharmaceutical compositions containing these silacrown ethers and the use of these materials as therapeutic agents are also described. | 2022-03-10 |
20220073544 | ORGANOSILANE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - Silane compounds derived from medium-chain fatty acids are generally disclosed herein. Methods of using such compounds, for example, as compatibilizing agents, are also disclosed herein, as well as methods of making such compounds, for example, from medium-chain fatty acids derived from natural oils. | 2022-03-10 |
20220073545 | SILANE-MODIFIED DIALLYL BISPHENOL COMPOUND AND PREPARATION METHOD THEREOF - A silane-modified diallyl bisphenol compound and a preparation method thereof are provided. A diallyl bisphenol compound with hydroxyl groups at both ends and a silane with at least one alkoxy group and at least one functional group having a crosslinkable double bond at the ends are reacted, so as to obtain a silane-modified diallyl bisphenol compound with a functional group having a crosslinkable double bond at the end. | 2022-03-10 |
20220073546 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES - A versatile reagent with a non-nucleotide monomeric unit comprising an enantiomeric center and having a ligand, and first and second coupling groups that are linked to the non-nucleotide monomeric unit. Such a reagent permits preparation of versatile nucleotide/non-nucleotide polymers, having any desired sequence of nucleotide and non-nucleotide monomeric units, each of the latter of which bear a desired ligand. These polymers can, for example, be used as probes which can exhibit enhanced sensitivity and/or which are capable of detecting a genus of nucleotides each species of which has a common target nucleotide sequence of interest bridged by different sequences not of interest. | 2022-03-10 |
20220073547 | Method of Preparing Phosphorus-Containing Flame Retardants and Their Use in Polymer Compositions - A phosphorus-containing flame retardant is produced by reacting at a reaction temperature a mixture including a metal or suitable metal compound and a stoichiometric excess relative to the metal or suitable metal compound of an unsubstituted or alkyl or aryl substituted phosphonic or pyrophosphonic acid, wherein the phosphonic or pyrophosphonic acid is in a molten state at the reaction temperature. The chemical composition of the resulting flame retardant product leads to excellent flame retardancy and exhibits high thermal stability. The presently disclosed flame retardants are useful, for example, in polymer compositions, particularly thermoplastics processed at high temperatures, over a wide range of applications. | 2022-03-10 |
20220073548 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE - This invention relates to the large-scale production of psilocybin for use in medicine. Move particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin. | 2022-03-10 |
20220073549 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis - The invention provides a new process for producing ruthenium complexes represented by the Formula 1. Invention provides also the use of ruthenium complexes represented by the Formula 1 as precatalysts and/or catalysts in olefin metathesis reactions. | 2022-03-10 |
20220073550 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME - Provided are an organometallic compound represented by Formula 1 and an organic light-emitting device including the organometallic compound. The organic light-emitting device includes; a first electrode; a second electrode facing the first electrode; an organic layer between the first electrode and the second electrode and comprising an emission layer; and at least one of the organometallic compound represented by Formula 1. | 2022-03-10 |
20220073551 | NON-PLANAR BLUE PHOSPHORESCENT EMITTERS BASED ON FUNCTIONALIZED IMIDAZOLYL GROUP - Compounds of General formula I and General Formula II have substituents which may result in a non-planar configuration. This molecular geometry may be effective in reducing excimer formation. The compounds described herein may therefore have improved blue color purity. The compounds have utility in light emitting diodes and light emitting devices. | 2022-03-10 |
20220073552 | REAGENT AND PROCESS FOR THE SITE-SPECIFIC DEOXYFLUORINATION OF PEPTIDES - The present invention refers to reagents and methods for preparing a peptide sequence having a [ | 2022-03-10 |
20220073553 | METHOD FOR EXTRACTING HIGH-PURITY POLYDEOXYRIBONUCLEOTIDE FROM SALMON TESTES - Disclosed is a method for extracting high-purity polydeoxyribonucleotide (PDRN) from salmon testes, including 1) separating semen and immature testicular regions from the testes of a salmonid fish, 2) gently grinding the immature testicular regions, followed by dilution with an artificial seminal plasma, 3) treating the dilution with a predetermined concentration of human chorionic gonadotropin (hCG) to induce artificial sexual maturation of the testicular cells to sperm, 4) centrifuging the testicular dilution after the passage of a predetermined time from the hCG treatment and collecting potentially motile sperm, and 5) extracting PDRN from the collected sperm. The method enables the production of raw materials for PDRN with a 100- to 200-fold higher purity from 20 mL (a maximum of 50 mL) of sperm (semen) collected at one time from a salmonid fish. In addition, the method enables the extraction of PDNR in high yield in a cost-effective and economically viable manner. | 2022-03-10 |
20220073554 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF - Provided are lincosamide compounds for the treatment of infectious diseases. The lincosaniides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamycin. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds. | 2022-03-10 |
20220073555 | GALECTIN-3 INHIBITING C-GLYCOSIDES - Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described. | 2022-03-10 |
20220073556 | PHOSPHOROAMIDATE ESTERS, AND USE AND SYNTHESIS THEREOF - Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules. | 2022-03-10 |
20220073557 | FLUORINATED BILE ACIDS - Compounds of general formula (1): | 2022-03-10 |
20220073558 | ORGANIC COMPOUNDS - The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents. | 2022-03-10 |
20220073559 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF - The present invention relates generally to the compound:
| 2022-03-10 |
20220073560 | METHOD FOR TRANSFERRING A BATCH PRODUCTION PROCESS TO A CONTINUOUS PRODUCTION PROCESS - Described herein is a method for transferring of batch production process for a monoclonal antibody to a continuous production process for the same monoclonal antibody. | 2022-03-10 |
20220073561 | MULTIDIMENSIONAL CHROMATOGRAPHY METHOD FOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES - The present disclosure relates to a sensitive, multidimensional chromatography method for extraction, detection, and quantification of non-conjugated cytotoxic agents and associated linker molecules used in cysteine based antibody-drug-conjugate production. | 2022-03-10 |
20220073562 | PEPTIDE FOR SKIN AGING PREVENTION AND WRINKLE REDUCTION, AND COMPOSITION COMPRISING SAME - Proposed is a peptide for skin anti-aging and anti-wrinkle, comprising a glycine-histidine-lysine tripeptide and polyarginine linked to the carboxy-terminus of the tripeptide, and a composition for skin anti-aging and anti-wrinkle comprising the peptide. The peptide and composition may enter the cytoplasm more rapidly and efficiently than a conventional GHK tripeptide, and may exhibit skin anti-aging and anti-wrinkle effects similar to those of the GHK tripeptide even at a lower concentration than that of the GHK tripeptide. | 2022-03-10 |
20220073563 | CARRIER PROTEIN FOR IMPROVING PROPERTIES OF BIOACTIVE PROTEIN - The present disclosure provides a carrier protein for improving properties of a bioactive protein. The carrier protein has a G-X-Y ternary repetitive structure, G is glycine, and X and Y are independently selected from proline, alanine and glutamic acid. The present disclosure further provides a fusion protein containing the carrier protein and the bioactive protein. The fusion protein of the present disclosure has improved biological properties, such as improved pharmacokinetic and physicochemical properties. | 2022-03-10 |
20220073564 | NOVEL TRIPLE-HELICAL POLYPEPTIDES LACKING BINDING AFFINITY FOR THE FC DOMAIN OF IMMUNOGLOBULIN AND USES THEREOF - The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin. | 2022-03-10 |
20220073565 | DE NOVO DESIGN OF PROTEIN SWITCHES FOR TUNABLE CONTROL OF PROTEIN DEGRADATION - Disclosed herein are non-naturally occurring cage polypeptides, kits and degron LOCKRs including the cage polypep-tides, and uses thereof, wherein the cage polypeptides include (a) a helical bundle, comprising between 2 and 7 alpha-helices, wherein the helical bundle includes: (i) a structural region; and (ii) a latch region, wherein the latch region composes a degron located within the latch region, wherein the structural region interacts with the latch region to prevent activity of the degron; and (b) amino acid linkers connecting each alpha helix | 2022-03-10 |
20220073566 | RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAME - The present invention provides a respiratory syncytial virus (RSV) recombinant fusion protein (F protein) in which a polymerization domain derived from a foreign protein is bound to the C terminal of a fusion protein (F protein) lacking a transmembrane domain of a wild-type respiratory syncytial virus (RSV) fusion protein (F protein). The recombinant fusion protein of the present invention is soluble and can retain an F protein trimer. Excellent immune-inducing effects can be expected from the recombinant fusion protein of the present invention, and vaccine composition containing same. | 2022-03-10 |
20220073567 | ACINETOBACTER BAUMANNII BACTERIOPHAGE MIKAB48 OR LYTIC PROTEIN DERIVED FROM THE BACTERIOPHAGE | 2022-03-10 |
20220073568 | VACCINES AGAINST HEPATITIS B VIRUS - The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection. | 2022-03-10 |
20220073569 | RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND ANTIBODY FC REGION AND USES THEREOF - Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein, and pharmaceutical compositions containing the same. | 2022-03-10 |
20220073570 | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa - Disclosed are immunogenic proteins from | 2022-03-10 |
20220073571 | PHOTORESPONSIVE PROTEIN AND UTILIZATION THEREOF - An excellent photosensitivity is exhibited by a protein including, at a position or positions corresponding to one or two or more positions selected from the group made of the following (1) to (3) in a first amino acid sequence represented by SEQ ID NO: 1: (1) positions 39, 94, 98, 102, 110, 113, 114, 162, 224, 225, 230, 231, and 235, (2) positions 53, 61, 68, 74, 76, 80, 130, 137, 194, 195, 198, 200, 204, 205, 209, 210, 253, and 254, and (3) positions 46, 83, 84, 87, 90, 91, 116, 117, 120, 124, 139, 142, 143, 146, 173, 214, 216, 217, 238, 242, and 245, an amino acid residue different from that in the first amino acid sequence, and that has channel activity. | 2022-03-10 |
20220073572 | PROCESS FOR EXTRACTING PHYCOCYANINS - The invention relates to a new process for extracting and purifying phycocyanins produced by fermenting microalgae, in particular produced by | 2022-03-10 |
20220073573 | TOMATO mSlBZR1L GENE AND USE THEREOF - The present disclosure relates to the field of biotechnology, and particularly to use of a tomato gene mSlBZR1L in changing the morphology of tomato fruits. The present disclosure discloses a tomato gene mSlBZR1L comprising a nucleotide sequence as set forth in SEQ ID No: 3, and the gene can extend the length of the tomato fruits. | 2022-03-10 |
20220073574 | FUSION PROTEIN WITH A TOXIN AND SCAFFOLD PROTEIN - The present invention relates to the field of structural biology and drug discovery. More specifically, the present invention relates to novel fusion proteins, their uses and methods in three-dimensional structural analysis of macromolecules, such as X-ray crystallography and high-resolution Cryo-EM, and their use in structure-based drug design and screening, and as pharmacological tools. Even more specifically, the invention relates to a functional fusion of a toxin and a scaffold protein wherein the folded scaffold protein interrupts the topology of the toxin by insertion in an exposed β-turn of a β-strand-containing domain of said toxin to form a rigid fusion protein that retains its high affinity target binding capacity. | 2022-03-10 |
20220073575 | Bacteriocins for Control of Salmonella enterica - The present invention relates to bacteriocins for control of | 2022-03-10 |
20220073576 | CODON-OPTIMISED COMPLEMENT FACTOR I - An isolated polynucleotide comprising a nucleotide sequence encoding a codon-optimised Complement Factor I (CFI). | 2022-03-10 |
20220073577 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS OF USE - Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 11, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 11, or fragments thereof) operably linked to a heterologous promoter are also disclosed. | 2022-03-10 |
20220073578 | METHODS OF TREATING AGING-RELATED DISORDERS - Provided herein are methods of killing or reducing the number of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, decreasing the accumulation of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, that include administering to the subject a therapeutically effective amount of one or more common gamma-chain family cytokine receptor activating agent(s) and/or one or more agent(s) that result(s) in a decrease in the activation of a TGF-β receptor. | 2022-03-10 |
20220073579 | DECORIN COMPOSITIONS AND USE THEREOF - The present invention relates to improved decorin compositions and methods of their production. | 2022-03-10 |
20220073580 | IL-37 VARIANTS - This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer. | 2022-03-10 |
20220073581 | ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGION - The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain. | 2022-03-10 |